ImmunityBio’s (IBRX) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $30.00 target price on the stock. Separately, BTIG Research started coverage on shares of ImmunityBio in a research note on Friday, January 10th. They issued a “buy” […]
D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $30.00 target price on the stock. Separately, BTIG Research started coverage on shares of ImmunityBio in a research note on Friday, January 10th. They issued a “buy” […]
